Rapid Micro Biosystems, Inc.
HealthcareNASDAQ:RPID · NASDAQ Global Select
-$0.12 today
Vol 0.14M · Avg 0.20M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$34.4M of revenue converted into -$50.1M of net income for the selected period. Gross margin is 14.4% and net margin is -149.8%, showing how much revenue survives after costs and taxes. EPS is $-1.11, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $33.6M +19.7% | $28.1M +24.6% | $22.5M +31.4% | $17.1M -26.3% | $23.2M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $26.0M -7.7% | $28.2M +0.6% | $28.0M +9.1% | $25.7M -17.1% | $31.0M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $7.6M +7079.8% | -$109.0K +98.0% | -$5.5M +35.8% | -$8.5M -10.3% | -$7.7M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 22.7% +23.0pp | -0.4% +24.0pp | -24.4% +25.5pp | -49.8% -16.5pp | -33.3% | 9.8% | 28.9% | 38.3% |
| Research & Development | $13.6M -6.8% | $14.6M +13.9% | $12.8M -0.4% | $12.9M +31.5% | $9.8M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $34.8M -1.1% | $35.2M -8.0% | $38.3M -8.5% | $41.8M +40.7% | $29.7M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $55.0M +10.4% | $49.8M -2.5% | $51.1M -6.6% | $54.7M +38.5% | $39.5M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $3.3M -3.3% | $3.4M +8.3% | $3.1M +9.4% | $2.8M +85.5% | $1.5M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$42.7M +1.8% | -$43.5M +11.8% | -$49.3M +15.7% | -$58.5M +15.5% | -$69.3M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -127.3% +27.8pp | -155.1% +64.0pp | -219.1% +122.6pp | -341.7% -43.6pp | -298.1% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$47.4M +5.1% | -$49.9M +11.7% | -$56.6M +10.5% | -$63.2M -33.8% | -$47.2M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -141.1% +36.9pp | -178.0% +73.2pp | -251.2% +117.8pp | -369.0% -165.7pp | -203.3% | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.5M -52.3% | $3.2M -24.8% | $4.2M +136.8% | $1.8M | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $1.1M | $0 | $0 | $0 -100.0% | $2.6M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $309.0K -89.9% | $3.1M -26.0% | $4.1M +124.7% | $1.8M +107.0% | -$26.2M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$47.1M -0.5% | -$46.9M +10.6% | -$52.4M +14.6% | -$61.4M +16.4% | -$73.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -140.2% +26.9pp | -167.1% +65.8pp | -232.9% +125.4pp | -358.3% -42.2pp | -316.1% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $40.0K +81.8% | $22.0K -29.0% | $31.0K +105.4% | -$576.0K -733.0% | $91.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$47.1M -0.5% | -$46.9M +10.6% | -$52.5M +13.7% | -$60.8M +17.3% | -$73.5M | $4.9B | $4.8B | $4.7B |
| Net Margin | -140.3% +26.9pp | -167.2% +65.8pp | -233.0% +121.9pp | -354.9% -38.4pp | -316.5% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +2.8% | -$1 +11.5% | -$1 +14.7% | -$1 +23.9% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +2.8% | -$1 +11.5% | -$1 +14.7% | -$1 +23.9% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $44.7M +2.5% | $43.6M +1.3% | $43.0M +1.3% | $42.5M +2.4% | $41.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $44.7M +2.5% | $43.6M +1.3% | $43.0M +1.3% | $42.5M +2.4% | $41.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Apyx Medical Corporation
NASDAQ:APYX
$196.39M
Lucid Diagnostics Inc.
NASDAQ:LUCD
$98.28M
AVITA Medical, Inc.
NASDAQ:RCEL
$97.14M
Cognition Therapeutics, Inc.
NASDAQ:CGTX
$89.03M
Owlet, Inc.
NYSE:OWLT
$84.14M
Sera Prognostics, Inc.
NASDAQ:SERA
$71.42M
LENSAR, Inc.
NASDAQ:LNSR
$70.45M
Vivani Medical, Inc.
NASDAQ:VANI
$64.99M
Tevogen Bio Holdings Inc.
TVGN
$43.84M
InspireMD, Inc.
NSPR
$34.19M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does RPID generate?
Rapid Micro Biosystems, Inc. (RPID) reported $33.59M of revenue in fiscal 2025.
Is RPID profitable?
Rapid Micro Biosystems, Inc. (RPID) reported -$47,123,000.00 of net income, with a net margin of -140.3%.
Explore More
Continue the stock analysis
Jump to another research area for this company.